Lantern Pharma Inc expected to post a loss of 38 cents a share - Earnings Preview
Lantern Pharma Inc <LTRN.OQ> expected to post a loss of 38 cents a share - Earnings Preview
Lantern Pharma Inc LTRN.OQ LTRN.O is expected to show no change in quarterly revenue when it reports results on August 13 for the period ending June 30 2026
LSEG's mean analyst estimate for Lantern Pharma Inc is for a loss of 38 cents per share.
The one available analyst rating on the shares is "buy".
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Lantern Pharma Inc is $25.00, about 799.3% above its last closing price of $2.78
This summary was machine generated August 7 at 14:00 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Receives Taiwan Approvals To Open Next Stage Of Phase 2 Harmonic Trial Of Lp-300 In Never-Smoker, Egfr-Mutant Nsclc
Brief: Lantern Pharma Reports Second Quarter 2026 Financial Results And Provides Business Update
Lantern Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Lantern Pharma Q2 operating loss widens on warrant expenses tied to higher stock price
Lantern Pharma Inc expected to post a loss of 38 cents a share - Earnings Preview